Earnings Releases·Nov 5, 2026, 4:16 PM ET

Dentsply Sirona — Q3 2026 Earnings Summary

Q3 2026 net sales declined 7.6% year-over-year to $836 million, while GAAP net loss narrowed significantly to $2 million ($0.01/share) from a $427 million loss in the prior year, driven by a $39 million one-time inventory estimate benefit and lower impairment charges; adjusted EPS fell 29.4% to $0.29.
The company updated its FY2026 outlook to $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30, explicitly excluding a $0.17 one-time tariff refund benefit.
Strategic progress includes Wellspect Healthcare achieving record quarterly sales (up 10.1%), the U.S. launch of the SurityTM Urinary Management System, and expansion of the U.S. dealer network, though Connected Technology and Orthodontic segments saw double-digit declines.
Capital allocation included $13 million in share repurchases during the quarter, bringing total YTD buybacks to $25 million, while cash reserves decreased to $195 million and total debt stood at $2.2 billion.